Alliancebernstein L.P. Boosts Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

Alliancebernstein L.P. grew its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 2.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 40,350 shares of the company’s stock after buying an additional 800 shares during the quarter. Alliancebernstein L.P. owned 0.06% of Vera Therapeutics worth $1,706,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. AlphaQuest LLC acquired a new position in Vera Therapeutics during the fourth quarter worth about $34,000. E Fund Management Co. Ltd. increased its stake in shares of Vera Therapeutics by 22.3% during the 4th quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company’s stock worth $262,000 after purchasing an additional 1,130 shares in the last quarter. Corebridge Financial Inc. raised its position in shares of Vera Therapeutics by 5.8% during the 4th quarter. Corebridge Financial Inc. now owns 22,047 shares of the company’s stock worth $932,000 after purchasing an additional 1,210 shares during the last quarter. KBC Group NV lifted its stake in Vera Therapeutics by 127.2% in the 4th quarter. KBC Group NV now owns 2,477 shares of the company’s stock valued at $105,000 after buying an additional 1,387 shares in the last quarter. Finally, Arizona State Retirement System grew its holdings in Vera Therapeutics by 22.9% during the 4th quarter. Arizona State Retirement System now owns 12,586 shares of the company’s stock valued at $532,000 after buying an additional 2,348 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Analyst Upgrades and Downgrades

VERA has been the topic of several recent research reports. Wolfe Research initiated coverage on Vera Therapeutics in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 price objective on the stock. The Goldman Sachs Group started coverage on shares of Vera Therapeutics in a research note on Tuesday, January 28th. They set a “buy” rating and a $58.00 price target on the stock. Guggenheim boosted their price objective on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 4th. One analyst has rated the stock with a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, Vera Therapeutics presently has an average rating of “Buy” and a consensus price target of $64.67.

Vera Therapeutics Trading Up 0.2 %

Shares of VERA opened at $21.29 on Friday. Vera Therapeutics, Inc. has a twelve month low of $18.53 and a twelve month high of $51.61. The firm has a market capitalization of $1.36 billion, a P/E ratio of -8.16 and a beta of 1.28. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. The stock’s fifty day simple moving average is $26.35 and its 200 day simple moving average is $36.68.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.11. On average, equities research analysts forecast that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.